PFBT
CRSP icon

Parkside Financial Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09K Hold
75
– – ﹤0.01% 1957
2026
Q1 		$3.57K Hold
75
– – ﹤0.01% 1925
2025
Q4 		$3.93K Buy
75
+25
+50% +$1.5K ﹤0.01% 1884
2025
Q3 		$3.24K Buy
+50
New +$2.87K ﹤0.01% 1862

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Parkside Financial Bank & Trust's CRSP Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 75 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1957.

Parkside Financial Bank & Trust first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Parkside Financial Bank & Trust held 75 shares of CRISPR Therapeutics worth $4.09K as of Q2 2026.
  • Parkside Financial Bank & Trust left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1957 holding.
  • Parkside Financial Bank & Trust first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.